fluoxetine has been researched along with naloxone in 37 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 6 (16.22) | 18.7374 |
1990's | 7 (18.92) | 18.2507 |
2000's | 12 (32.43) | 29.6817 |
2010's | 10 (27.03) | 24.3611 |
2020's | 2 (5.41) | 2.80 |
Authors | Studies |
---|---|
Bauer, C; Caldwell, L; Kinnier, WJ; Lancaster, J; McMillan, B; Price, CH; Sweetnam, PM | 1 |
Topliss, JG; Yoshida, F | 1 |
Adkison, KK; Humphreys, JE; Mahar Doan, KM; Polli, JW; Serabjit-Singh, CJ; Shampine, LJ; Webster, LO; Wring, SA | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
Chen, X; Lin, X; Skolnik, S; Wang, J | 1 |
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
Chen, L; Fei, J; Mei, Y; Ren, S; Yan, SF; Zeng, J; Zhang, JZ | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Margalit, D; Segal, M | 1 |
Lemaire, I; Lemaire, S; Tseng, R | 1 |
Cherkin, A; Flood, JF; Smith, GE | 1 |
Maickel, RP; Spratto, GR; Tocco, DR | 1 |
Bemis, KG; Hymson, DL; Hynes, MD; Lochner, MA | 1 |
Cerrito, F; Preziosi, P; Vacca, M | 1 |
Bastide, P; Coudert, P; Rubat, C; Tronche, P | 1 |
Hagan, MM; Moss, DE | 1 |
Crosbie, GV; Grice, JE; Hockings, GI; Jackson, RV; Torpy, DJ; Walters, MM | 1 |
Backer, MM; Pick, CG; Schreiber, S | 1 |
Cabello, CE; Hagan, MM; Hanscom, DR; Holguin, FD; Moss, DE | 1 |
Casarosa, E; Genazzani, AR; Luisi, S; Parrini, D; Petraglia, F; Rubino, S; Spinetti, A; Stomati, M | 1 |
Hassanpour, M; Nayebi, AR; Rezazadeh, H | 1 |
Casarosa, E; Florio, P; Genazzani, AD; Genazzani, AR; Lombardi, I; Luisi, M; Petraglia, F; Quirici, B | 1 |
Jain, NK; Kulkarni, SK; Singh, VP | 1 |
Jain, NK; Kulkarni, SK; Patil, CS; Singh, A; Singh, VP | 1 |
Cador, M; Koob, GF; Stinus, L; Zorrilla, EP | 1 |
Dziedzicka-Wasylewska, M; Filip, M; Inan, SY; Przegaliński, E; Wydra, K | 1 |
Chen, JY; Chen, YA; Tao, PL; Wu, CC; Yeh, GC | 1 |
Forray, MI; Gysling, K; Sotomayor, R | 1 |
Anjaneyulu, M; Chopra, K | 1 |
Alfinito, PD; Cosmi, S; Deecher, DC; Leventhal, L; Maswood, N | 1 |
Audi, EA; Biesdorf, C; Graeff, FG; Roncon, CM; Santana, RG; Zangrossi, H | 1 |
Naranjo, J; Pollard, EM; Sprung, J; Warner, MA; Warner, ME; Weingarten, TN | 1 |
Davoudi, S; Dolatshahi, M; Ghorbanzadeh, B; Naserzadeh, R; Paridar, Y | 1 |
Keidan, L; Pick, CG; Schreiber, S | 1 |
2 review(s) available for fluoxetine and naloxone
Article | Year |
---|---|
The role of receptor binding in drug discovery.
Topics: Animals; Drug Design; Humans; Receptors, Drug | 1993 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for fluoxetine and naloxone
Article | Year |
---|---|
Diurnal effects of fluoxetine and naloxone on the human hypothalamic-pituitary-adrenal axis.
Topics: Administration, Oral; Adrenocorticotropic Hormone; Adult; Chronotherapy; Double-Blind Method; Drug Administration Schedule; Drug Synergism; Female; Fluoxetine; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Injections, Intravenous; Male; Middle Aged; Naloxone; Pituitary-Adrenal System | 1997 |
Endocrine, neuroendocrine and behavioral effects of oral dehydroepiandrosterone sulfate supplementation in postmenopausal women.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Androstenedione; Area Under Curve; beta-Endorphin; Climacteric; Clonidine; Dehydroepiandrosterone; Estradiol; Estrone; Female; Fluoxetine; Humans; Middle Aged; Multivariate Analysis; Naloxone; Narcotic Antagonists; Prospective Studies; Radioimmunoassay; Selective Serotonin Reuptake Inhibitors; Somatostatin; Testosterone | 1999 |
33 other study(ies) available for fluoxetine and naloxone
Article | Year |
---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Cell Line; Cell Membrane Permeability; Central Nervous System Agents; Dogs; Drug Delivery Systems; Permeability; Pharmaceutical Preparations | 2002 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Biological Transport; Caco-2 Cells; Chromatography, Liquid; Dibenzocycloheptenes; Diketopiperazines; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Intestinal Absorption; Mass Spectrometry; Models, Biological; Neoplasm Proteins; Pharmaceutical Preparations; Predictive Value of Tests; Propionates; Quinolines; Substrate Specificity | 2011 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
Topics: Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Kinetics; Microsomes, Liver; Models, Molecular; Molecular Dynamics Simulation; Substrate Specificity | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
A pharmacologic study of analgesia produced by stimulation of the nucleus locus coeruleus.
Topics: Adrenergic alpha-Antagonists; Analgesia; Animals; Clonidine; Cyproheptadine; Ditiocarb; Electric Stimulation; Fluoxetine; Hydroxydopamines; Locus Coeruleus; Male; Naloxone; Rats; Reserpine; Self Stimulation | 1979 |
Systemic administration of beta-endorphin: potent hypotensive effect involving a serotonergic pathway.
Topics: Blood Pressure; Dose-Response Relationship, Drug; Endorphins; Fenclonine; Fluoxetine; Naloxone; Neural Pathways; Receptors, Serotonin; Serotonin; Serotonin Antagonists | 1978 |
Memory enhancement in mice: role of drug dose and training-testing interval.
Topics: Adrenocorticotropic Hormone; Animals; Arecoline; Avoidance Learning; Clonidine; Dose-Response Relationship, Drug; Fluoxetine; Male; Memory; Memory, Short-Term; Mice; Naloxone; Peptide Fragments; Piribedil; Time Factors | 1988 |
Differential analgetic actions of amphetamine enantiomers in the mouse: a drug-drug interaction study.
Topics: Amphetamine; Analgesics; Animals; Dextroamphetamine; Dopamine; Drug Interactions; Fenclonine; Fluoxetine; Male; Metergoline; Mice; Morphine; Naloxone; Norepinephrine; Pimozide; Serotonin; Stereoisomerism | 1985 |
Fluoxetine, a selective inhibitor of serotonin uptake, potentiates morphine analgesia without altering its discriminative stimulus properties or affinity for opioid receptors.
Topics: Animals; Binding, Competitive; Brain; Discrimination, Psychological; Drug Synergism; Enkephalin, Leucine; Enkephalin, Leucine-2-Alanine; Female; Fluoxetine; Male; Morphine; Naloxone; Pain; Propylamines; Rats; Rats, Inbred Strains; Receptors, Opioid; Serotonin | 1985 |
Effects of naloxone on the secretion of prolactin and corticosterone induced by 5-hydroxytryptophan and a serotonergic agonist, mCPP.
Topics: 5-Hydroxytryptophan; Animals; Corticosterone; Fluoxetine; Male; Naloxone; Piperazines; Prolactin; Rats; Rats, Inbred Strains | 1983 |
Behavioural profile of two potential antidepressant pyridazine derivatives including arylpiperazinyl moieties in their structure, in mice.
Topics: 5-Hydroxytryptophan; Analgesia; Animals; Antidepressive Agents; Apomorphine; Behavior, Animal; Blepharoptosis; Citalopram; Clomipramine; Drug Interactions; Fluoxetine; Hypothermia; Imipramine; Injections, Intraperitoneal; Injections, Subcutaneous; Male; Mice; Models, Molecular; Motor Activity; Naloxone; Piperazines; Pyridazines; Reserpine; Structure-Activity Relationship; Swimming; Trazodone; Yohimbine | 1995 |
Effect of naloxone and antidepressants on hyperphagia produced by peptide YY.
Topics: Animals; Antidepressive Agents; Clomipramine; Dose-Response Relationship, Drug; Feeding Behavior; Female; Fluoxetine; Gastrointestinal Hormones; Injections, Intraperitoneal; Injections, Intraventricular; Naloxone; Peptide YY; Peptides; Rats; Rats, Sprague-Dawley | 1993 |
Interactions between different antidepressants and morphine alter gastrointestinal transit in mice.
Topics: Analgesics, Opioid; Animals; Antidepressive Agents, Second-Generation; Dose-Response Relationship, Drug; Drug Interactions; Fluoxetine; Gastrointestinal Transit; Male; Mianserin; Mice; Mice, Inbred ICR; Morphine; Naloxone; Narcotic Antagonists; Rats | 1997 |
Combined naloxone and fluoxetine on deprivation-induced binge eating of palatable foods in rats.
Topics: Animals; Antidepressive Agents, Second-Generation; Appetite Depressants; Dietary Carbohydrates; Dietary Fats; Feeding Behavior; Fluoxetine; Food Deprivation; Food Preferences; Male; Naloxone; Narcotic Antagonists; Rats; Rats, Sprague-Dawley; Time Factors | 1997 |
Effect of chronic and acute administration of fluoxetine and its additive effect with morphine on the behavioural response in the formalin test in rats.
Topics: 5,7-Dihydroxytryptamine; Analgesics, Opioid; Animals; Drug Synergism; Fluoxetine; Formaldehyde; Injections, Intraperitoneal; Male; Morphine; Naloxone; Narcotic Antagonists; Pain Measurement; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Serotonin Agents; Time Factors | 2001 |
Neuroendocrine effects of raloxifene hydrochloride in postmenopausal women.
Topics: Adrenergic alpha-Agonists; Aged; beta-Endorphin; Clonidine; Drug Interactions; Female; Fluoxetine; Humans; Middle Aged; Naloxone; Narcotic Antagonists; Neurosecretory Systems; Postmenopause; Pregnanolone; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Selective Serotonin Reuptake Inhibitors | 2001 |
Fluoxetine suppresses morphine tolerance and dependence: modulation of NO-cGMP/DA/serotoninergic pathways.
Topics: Animals; Arginine; Body Weight; Cyclic GMP; Depression, Chemical; Diarrhea; Dopamine; Drug Interactions; Drug Tolerance; Female; Fluoxetine; Male; Mice; Morphine Dependence; Naloxone; Narcotic Antagonists; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Selective Serotonin Reuptake Inhibitors; Serotonin; Substance Withdrawal Syndrome | 2003 |
Paradoxical effects of opioid antagonist naloxone on SSRI-induced analgesia and tolerance in mice.
Topics: Analgesics; Animals; Citalopram; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Tolerance; Fluoxetine; Injections, Intraperitoneal; Injections, Spinal; Mice; Naloxone; Narcotic Antagonists; Selective Serotonin Reuptake Inhibitors | 2003 |
Buprenorphine and a CRF1 antagonist block the acquisition of opiate withdrawal-induced conditioned place aversion in rats.
Topics: Acamprosate; Analgesics, Opioid; Animals; Antidepressive Agents, Second-Generation; Avoidance Learning; Buprenorphine; Conditioning, Operant; Dose-Response Relationship, Drug; Drug Implants; Fluoxetine; Lisuride; Male; Morphine; Naloxone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Pyrimidines; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Corticotropin-Releasing Hormone; Substance Withdrawal Syndrome; Taurine | 2005 |
Opioid and monoamine systems mediate the discriminative stimulus of tramadol in rats.
Topics: Adrenergic Uptake Inhibitors; Analgesics, Opioid; Animals; Antidepressive Agents; Biogenic Monoamines; Conditioning, Operant; Cyclohexanols; Cyclopropanes; Discrimination, Psychological; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Synergism; Fluoxetine; Male; Milnacipran; Morphine; Morpholines; Naloxone; Narcotic Antagonists; Nomifensine; Rats; Rats, Wistar; Reboxetine; Receptors, Opioid, mu; Selective Serotonin Reuptake Inhibitors; Sodium Chloride; Tramadol; Venlafaxine Hydrochloride | 2004 |
Serotonin reuptake inhibitors attenuate morphine withdrawal syndrome in neonatal rats passively exposed to morphine.
Topics: Animals; Animals, Newborn; Behavior, Animal; Citalopram; Clomipramine; Female; Fluoxetine; Maternal-Fetal Exchange; Morphine Dependence; Naloxone; Narcotic Antagonists; Pregnancy; Pregnancy Complications; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndrome | 2005 |
Acute morphine administration increases extracellular DA levels in the rat lateral septum by decreasing the GABAergic inhibitory tone in the ventral tegmental area.
Topics: Analysis of Variance; Animals; Dopamine; Drug Administration Schedule; Extracellular Fluid; Fluoxetine; gamma-Aminobutyric Acid; Male; Microdialysis; Morphine; Naloxone; Narcotic Antagonists; Narcotics; Neural Inhibition; Neural Pathways; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Septum of Brain; Serotonin; Statistics, Nonparametric; Ventral Tegmental Area | 2005 |
Possible involvement of cholinergic and opioid receptor mechanisms in fluoxetine mediated antinociception response in streptozotocin-induced diabetic mice.
Topics: Analgesics; Animals; Atropine; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Fluoxetine; Male; Mice; Muscarinic Antagonists; Naloxone; Narcotic Antagonists; Pain; Pain Measurement; Pain Threshold; Receptors, Muscarinic; Receptors, Opioid; Secologanin Tryptamine Alkaloids; Serotonin Antagonists | 2006 |
The role of the selective serotonin reuptake inhibitor fluoxetine in temperature regulation in ovariectomized rat models.
Topics: Animals; Body Temperature Regulation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Combinations; Female; Fluoxetine; Hot Flashes; Morphine Dependence; Naloxone; Ovariectomy; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin 5-HT1 Receptor Antagonists; Telemetry | 2006 |
The panicolytic-like effect of fluoxetine in the elevated T-maze is mediated by serotonin-induced activation of endogenous opioids in the dorsal periaqueductal grey.
Topics: Animals; Antidepressive Agents, Second-Generation; Fluoxetine; Male; Maze Learning; Motor Activity; Naloxone; Opioid Peptides; Panic Disorder; Periaqueductal Gray; Rats; Rats, Wistar; Serotonin | 2012 |
Serotonergic medications, herbal supplements, and perioperative serotonin syndrome.
Topics: Aged; Curcuma; Dietary Supplements; Drug Interactions; Fentanyl; Fluoxetine; Humans; Male; Midazolam; Naloxone; Perioperative Period; Serotonin Agents; Serotonin Syndrome; Time Factors; Trazodone; Young Adult | 2017 |
Pharmacological evidence for the involvement of the opioid system in the antidepressant-like effect of simvastatin in mice: Without tolerance and withdrawal syndrome.
Topics: Analgesics, Opioid; Animals; Antidepressive Agents; Behavior, Animal; Depression; Drug Tolerance; Fluoxetine; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Locomotion; Mice; Morphine; Naloxone; Narcotic Antagonists; Open Field Test; Receptors, Opioid; Simvastatin; Substance Withdrawal Syndrome; Swimming | 2020 |
Treatment-Resistant Depression (TRD): Is the Opioid System Involved?
Topics: Analgesics, Opioid; Animals; Antidepressive Agents; Depression; Dose-Response Relationship, Drug; Fluoxetine; Fluvoxamine; Mianserin; Mice; Mirtazapine; Moclobemide; Naloxone; Reboxetine; Trazodone; Venlafaxine Hydrochloride | 2023 |